CD20 POSITIVE
Clinical trials for CD20 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new CD20 POSITIVE trials appear
Sign up with your email to follow new studies for CD20 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo tackles tough lymphoma in older and relapsed patients
Disease control OngoingThis study tests a combination of two drugs, ibrutinib and rituximab, in people with mantle cell lymphoma that has returned or not responded to treatment, or in older adults newly diagnosed. The goal is to see how well the drugs work together to shrink or control the cancer. Abou…
Matched conditions: CD20 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Double-targeted cell therapy takes on hard-to-treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…
Matched conditions: CD20 POSITIVE
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tests two drugs, venetoclax and acalabrutinib, given together to people with mantle cell lymphoma that came back or didn't respond to prior therapy. The goal is to see if the combination can shrink or eliminate cancer. 32 adults with this specific blood cancer are part…
Matched conditions: CD20 POSITIVE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 01, 2026 15:57 UTC
-
New hope for tough lymphoma: drug combo shows promise in early trial
Disease control OngoingThis early-phase study tested a new combination of drugs (carfilzomib plus standard chemotherapy) in 29 adults with diffuse large B-cell lymphoma that had come back or not responded to prior treatment. The main goals were to find the safest dose of carfilzomib and see how well th…
Matched conditions: CD20 POSITIVE
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC